Core Viewpoint - The performance of consumer-themed funds has improved after expanding and updating the definition of the consumer industry, despite the recent decline in the stock prices of heavily weighted consumer stocks [1][2]. Group 1: Consumer Fund Performance - Consumer-themed funds have shown a divergence in performance, with some actively managed equity consumer funds and passive consumer ETFs performing well, while traditional consumer stocks have faced significant downward pressure [1][2]. - The performance difference among consumer ETFs is largely attributed to how fund managers and indices define "consumption," with those including technology stocks seeing better returns [2][3]. Group 2: Inclusion of Technology Stocks - The inclusion of technology stocks in consumer industry indices has helped mitigate the impact of declines in traditional consumer stocks on related ETFs [3]. - Some consumer funds have strategically broadened their investment scope to include sectors like technology, semiconductors, and innovative pharmaceuticals, which has positively influenced their performance [4][5]. Group 3: Market Trends and Strategies - The current market consensus is shifting towards technology-driven investments, particularly in artificial intelligence, which is becoming a dominant theme in the investment landscape [6][7]. - Fund managers are increasingly focusing on technology characteristics while downplaying traditional consumer sectors, as consumer stocks are currently experiencing valuation compression [6][7]. Group 4: Fund Examples and Strategies - Specific funds, such as the Guorong Huagang Deep Consumption Fund, have achieved significant returns (58.56%) by expanding their definition of consumption to include high-growth sectors like AI and semiconductors [4]. - Other funds, like the Southern Consumption Upgrade Fund and Great Wall Consumption Value Fund, have also enhanced their performance by incorporating hard technology sectors into their portfolios [5].

2025年9月29日，港股上市公司投资日志如下： | 类别 | 公司 | | --- | --- | | | 长风药业 | | 新股活动 | (招股中) | | | 冠军科技集团 | | | OKURA HOLDINGS | | | 健康160 | | | 恒和集团 | | | 中国生态旅游 | | 业绩公布日 | 诺科达科技 | | | PALADIN | | | 大象未来集团 | | | 宝联控股 | | | 时代集团控股 | | | 华音国际控股 QPL INT'L | | | 泰格医药 | | | 南旋控股 | | | 第一拖拉机股份 | | 股东大会召开日 | 财华社集团 | | | 绿色经济 | | | MOS HOUSE | | | 龙升集团控股 | | | 华亿金控 | | | 新华通讯频媒 | | 停复牌 | | | | （复牌） | | 分红派息 | 安乐工程 | | | （派息日） | | | 固生堂 | | | （派息日） | | | 中华汽车 | | | （除净日） | | | 中国船舶租赁 | | | （除净日） | 第一拖拉机股份 （除净日） 上美股份 （除净日） （除净日） 亿 ...

Core Viewpoint - The AI healthcare sector is still in its nurturing phase, but the investment enthusiasm has attracted significant QDII fund allocations, with a focus on overseas revenue expansion to address high valuation concerns [1][3]. Group 1: Investment Trends - Public funds are increasingly focusing on AI healthcare, with companies like JingTai Holdings, GuShengTang, YiDu Technology, and iFlyTek actively seeking growth through international expansion [3][4]. - JingTai Holdings has successfully assisted a pharmaceutical company in obtaining clinical trial approval in Australia, highlighting its strong overseas business performance [3]. - YiDu Technology has reported that its international revenue growth significantly outpaces domestic growth, with contributions from Brunei reaching over 100 million yuan, accounting for 14.36% of its total revenue [3][4]. Group 2: Valuation Concerns - Despite the growth potential, fund managers express concerns over high valuations and profitability challenges faced by many AI healthcare companies, leading some QDII funds to prefer US stocks [6][7]. - For instance, Mirxes has a market capitalization exceeding 17 billion HKD, while its competitor Grail, despite having a much larger revenue, has a lower market cap, indicating a premium valuation in the Hong Kong market [6][7]. Group 3: Future Outlook - Some fund managers believe that the current high valuations are linked to the different stages of commercialization, with US companies having a head start [9]. - The AI healthcare sector is expected to see significant growth as domestic companies accelerate their development, particularly in areas like brain-computer interfaces, which are projected to transition from laboratory to clinical applications within 1-2 years [10].

Summary of Key Points Core Viewpoint - The company, Guosheng Tang, has been actively repurchasing its shares, indicating a strategy to support its stock price amid a recent decline in share value [2]. Share Buyback Details - On September 26, the company repurchased 100,000 shares at prices ranging from HKD 30.500 to HKD 30.880, totaling HKD 3.064 million [2]. - The stock closed at HKD 30.420 on the same day, reflecting a decrease of 2.25%, with a total trading volume of HKD 58.2646 million [2]. - Since September 10, the company has conducted share buybacks for 13 consecutive days, acquiring a total of 1.4272 million shares for a cumulative amount of HKD 46.2512 million, during which the stock price has dropped by 8.62% [2]. - Year-to-date, the company has executed 36 buybacks, totaling 4.3818 million shares and an aggregate buyback amount of HKD 141 million [2]. Buyback Price Trends - The highest buyback price recorded was HKD 37.700 on June 6, while the lowest was HKD 28.100 on April 7 [3]. - The buyback activity shows a consistent effort to stabilize the stock price, with varying amounts and prices over the months [3].

GUSHENGTANG HOLDINGS LIMITED 固 生 堂 控 股 有 限 公 司 (Incorporated under the laws of the Cayman Islands with limited liability) （根據開曼群島法律註冊成立的有限公司） (Stock Code 股份代號: 2273) NOTIFICATION LETTER 通知信函 29 September 2025 Dear Non-Registered Shareholder(1) , GUSHENGTANG HOLDINGS LIMITED ("Gushengtang") — Notification of publication of 2025 Interim Report ("Current Corporate Communication") on the Company's website The Current Corporate Communication of Gushengtang, in both English and Chinese versions, is available on t ...

Dear Shareholder, 29 September 2025 GUSHENGTANG HOLDINGS LIMITED (the "Company") – Notification of publication of 2025 Interim Report ("Current Corporate Communications") NOTIFICATION LETTER 通知信函 GUSHENGTANG HOLDINGS LIMITED 固 生 堂 控 股 有 限 公 司 (Incorporated under the laws of the Cayman Islands with limited liability) （根據開曼群島法律註冊成立的有限公司） （Stock Code股份代號：2273） Note: Corporate Communications include but not limited to (a) directors' reports, annual accounts together with the auditors' reports and, where applica ...

[Corporate Information](index=3&type=section&id=Corporate%20Information) This section provides an overview of the company's governance structure, including board composition, committees, and fundamental corporate details [Directors and Committees](index=3&type=section&id=Directors%20and%20Committees) The Board of Directors comprises executive, non-executive, and independent non-executive directors, with established audit, remuneration, and nomination committees - Executive Director Mr. Tu Zhiliang serves as Chairman[6](index=6&type=chunk)[8](index=8&type=chunk) - Mr. Gao Jian ceased to be a non-executive director effective June 20, 2025[6](index=6&type=chunk)[8](index=8&type=chunk) - Ms. Wang Lan was appointed as an independent non-executive director and Chairman of the Remuneration Committee effective March 31, 2025[6](index=6&type=chunk)[7](index=7&type=chunk)[8](index=8&type=chunk) - Ms. Jin Xu resigned as an independent non-executive director and member of the Remuneration/Nomination Committee effective March 31, 2025[6](index=6&type=chunk)[7](index=7&type=chunk)[8](index=8&type=chunk) [Company Details](index=4&type=section&id=Company%20Details) The company is registered in the Cayman Islands, with its China headquarters in Guangzhou and principal place of business in Hong Kong - Registered office in the Cayman Islands, China headquarters in Nansha District, Guangzhou City, and principal place of business in Wan Chai, Queen's Road East, Hong Kong[10](index=10&type=chunk)[11](index=11&type=chunk) - Principal bankers are Industrial and Commercial Bank of China and Shanghai Pudong Development Bank[13](index=13&type=chunk)[14](index=14&type=chunk) - Auditor is Ernst & Young, and Hong Kong legal counsel is Tian Yuan Law Firm[13](index=13&type=chunk)[14](index=14&type=chunk) - Stock code is 2273, and the company website is www.gstzy.cn[14](index=14&type=chunk) [Financial Highlights](index=6&type=section&id=Financial%20Highlights) For the six months ended June 30, 2025, the Group's revenue increased by 9.5% year-on-year to **RMB 1,494.9 million**, with net profit growing by 41.6% to **RMB 152.0 million** Financial Highlights for the Six Months Ended June 30, 2025 | Indicator | 2025 (RMB thousand) | 2024 (RMB thousand) | Change (RMB thousand) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Revenue | 1,494,891 | 1,364,979 | 129,912 | 9.5% | | Gross Profit | 457,856 | 401,212 | 56,644 | 14.1% | | EBITDA | 265,003 | 193,047 | 71,956 | 37.3% | | Profit Before Tax | 179,992 | 125,085 | 54,907 | 43.9% | | Net Profit | 151,954 | 107,275 | 44,679 | 41.6% | | Adjusted Net Profit | 170,389 | 147,888 | 22,501 | 15.2% | | Basic Earnings Per Share (RMB) | 0.63 | 0.44 | 0.19 | 43.2% | | Diluted Earnings Per Share (RMB) | 0.62 | 0.43 | 0.19 | 44.2% | | Gross Profit Margin | 30.6% | 29.4% | N/A | 1.2% | | Net Profit Margin | 10.2% | 7.9% | N/A | 2.3% | | Adjusted Net Profit Margin | 11.4% | 10.8% | N/A | 0.6% | [Management Discussion and Analysis](index=7&type=section&id=Management%20Discussion%20and%20Analysis) This section provides an in-depth analysis of the Group's operational performance, financial position, and future strategic outlook [BUSINESS REVIEW](index=7&type=section&id=BUSINESS%20REVIEW) The Group, a Chinese Traditional Chinese Medicine (TCM) healthcare service provider, offers comprehensive services and products through its online and offline network - The Group is committed to providing comprehensive TCM healthcare services and products through its offline medical institutions and online healthcare platform network, emphasizing basic medical care[17](index=17&type=chunk)[20](index=20&type=chunk) - The Group combines TCM and Western medicine diagnostics to offer comprehensive healthcare solutions, focusing on chronic disease management and long-term follow-up and health management for customers[23](index=23&type=chunk)[25](index=25&type=chunk) [Digitalization & AI Empowerment](index=8&type=section&id=Digitalization%20%26%20AI%20Empowerment) The Group continuously strengthens operational standardization and digitalization, implementing various systems and launching AI-powered services to enhance efficiency and customer experience - Established a digital clerk system, presenting operational data in digital reports to enhance interaction between offline medical institutions and customers, increasing patient visits and return rates[27](index=27&type=chunk) - Developed a medical CRM system, integrating the development and management of medical professional teams, utilizing digital statistics for daily operations and management analysis to improve operational efficiency[27](index=27&type=chunk) - Built an intelligent prescription review and compliance platform, embedding national medical insurance reimbursement schemes and local medical insurance bureau regulations, utilizing information technology for compliance control[31](index=31&type=chunk) - Constructed a closed-loop ERP system for the entire business process, enhancing management efficiency through comprehensive system management of supply chain, sales, inventory, and accounting[31](index=31&type=chunk) - Launched the first "National TCM AI Avatar" in June 2025, followed by 10 major AI avatars by August, covering 8 core TCM specialties such as oncology and dermatology, and introduced an AI health assistant to empower TCM services with AI technology[31](index=31&type=chunk) [Policy Support & Industry Trends](index=9&type=section&id=Policy%20Support%20%26%20Industry%20Trends) The Chinese government continues to introduce favorable policies supporting the inheritance and innovative development of Traditional Chinese Medicine (TCM) - In February 2021, the Chinese government issued "Several Policy Measures on Accelerating the Characteristic Development of Traditional Chinese Medicine," encouraging social forces to establish chain-operated renowned TCM clinics to provide first-class TCM services[29](index=29&type=chunk)[30](index=30&type=chunk) - In December 2021, the National Healthcare Security Administration and the National Administration of Traditional Chinese Medicine jointly issued "Guiding Opinions on Medical Insurance Support for the Inheritance and Innovative Development of Traditional Chinese Medicine," supporting the development of "Internet+" TCM and its inclusion in medical insurance, adjusting TCM medical service prices, and allowing TCM medical institutions to independently price their in-house preparations[33](index=33&type=chunk)[35](index=35&type=chunk) - In March 2022, the "Physicians Law of the People's Republic of China" came into effect, encouraging physicians to regularly provide services at medical and health institutions below the county level; in the same year, the "14th Five-Year Plan for the Improvement of Grassroots Traditional Chinese Medicine Service Capacity" was released, encouraging social forces to establish TCM medical institutions at the grassroots level[34](index=34&type=chunk)[36](index=36&type=chunk) - In February 2023, the General Office of the State Council issued the "Implementation Plan for Major Projects to Revitalize and Develop Traditional Chinese Medicine," focusing on enhancing TCM capabilities at grassroots medical institutions and cultivating high-quality TCM talents[37](index=37&type=chunk)[38](index=38&type=chunk) - In June 2024, the General Office of the State Council issued "Key Tasks for Deepening the Reform of the Medical and Health System in 2024," supporting pilot programs for advantageous TCM therapies, integrated medical group reforms, inheritance and innovative development of TCM, talent cultivation, and productization of in-house preparations[40](index=40&type=chunk)[42](index=42&type=chunk) - In July 2024, the National Administration of Traditional Chinese Medicine and the National Data Administration jointly issued "Several Opinions on Promoting the Development of Digital Traditional Chinese Medicine," planning to integrate big data, artificial intelligence, and other emerging digital technologies into the inheritance and innovation of TCM within the next three to five years, accelerating intelligent transformation[41](index=41&type=chunk)[43](index=43&type=chunk) - In March 2025, the General Office of the State Council issued "Opinions on Improving the Quality of Traditional Chinese Medicine and Promoting the High-Quality Development of the Traditional Chinese Medicine Industry," aiming to comprehensively enhance the quality of TCM and promote its high-quality industrial development, bringing new opportunities for the Group[44](index=44&type=chunk)[46](index=46&type=chunk) [Revenue Sources & Network Expansion](index=13&type=section&id=Revenue%20Sources%20%26%20Network%20Expansion) During the reporting period, the Group's revenue primarily stemmed from providing healthcare solutions and selling healthcare products - During the reporting period, the Group's revenue primarily came from providing healthcare solutions and selling healthcare products[45](index=45&type=chunk)[47](index=47&type=chunk) - As of June 30, 2025, the Group owned and operated 83 medical institutions in 20 cities in China and 1 medical institution in Singapore, all operating under the "Gushengtang" brand[49](index=49&type=chunk)[51](index=51&type=chunk) - During the reporting period, the Group expanded its business footprint through strategic acquisitions and organic growth, including acquiring 90% equity in Wuhan Future TCM Hospital, 100% in Wuxi Tongkang TCM Hospital, 100% in Beijing Bohua Jingkang TCM Hospital, 100% in Changshu Guangren Hospital, and controlling stakes in Tianjin Pingan Comprehensive Clinic and Shenzhen Tianyuan TCM Anorectal Hospital[50](index=50&type=chunk)[52](index

Group 1 - The company, Guoshengtang (02273), announced a share buyback plan [1] - The total amount allocated for the buyback is HKD 3.064 million [1] - The company plans to repurchase 100,000 shares at a price range of HKD 30.50 to HKD 30.88 per share [1]

Core Viewpoint - The company, Guoshengtang (02273), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Categories Company Actions - Guoshengtang plans to repurchase 100,000 shares at a total cost of HKD 3.064 million [1] - The buyback price ranges from HKD 30.50 to HKD 30.88 per share [1]

Group 1 - Company announced a share buyback of 100,000 shares at a cost of HKD 3.064 million on September 26 [1]